Salvia BioElectronics

About Salvia BioElectronics

Salvia BioElectronics is a clinical-stage medical device company developing a novel bioelectronic therapy for chronic migraine. The company was founded in 2017 in Eindhoven, the Netherlands, by Hubert Martens, Wim Pollet, and Daniël Schobben. The founding team combines significant entrepreneurial and technical experience in the MedTech sector; CEO Hubert Martens, for instance, previously co-founded Sapiens Steering Brain Stimulation, a company focused on Parkinson's treatment that was acquired by Medtronic in 2014.

The company's core product is the MySalvia Therapy, a neuromodulation system designed to reduce the frequency and intensity of migraine attacks for patients who have not responded to other treatments. The therapy utilizes ultra-thin, flexible bioelectronic implants placed subcutaneously in the forehead and back of the head through a minimally invasive procedure. Patients can activate the device on-demand by pressing a button on an external wearable, which delivers gentle electrical pulses to the nerves associated with migraine. This patient-centered approach aims to provide drug-free, lasting relief with reduced surgical complexity and recovery time compared to conventional neurostimulation technologies. The system has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

Salvia operates on a business model focused on developing and commercializing this proprietary medical device for a global market, including the United States, Europe, and Australia. The company is advancing its technology through rigorous clinical evaluation, including the multi-center, double-blind RECLAIM study, to secure regulatory approvals for market entry. Salvia has successfully raised significant capital to fund these efforts, closing a $60 million (€53 million) Series B round in May 2025 led by Innovation Industries and supported by a syndicate of new and existing investors such as Invest-NL, EIC Fund, Panakès Partners, and Dolby Family Ventures. In addition to its primary focus on chronic migraine, the company is also exploring the potential application of its technology for treating cluster headaches.